Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 2/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | CENPE | Q02224 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776662 | 0.91 | TRPV1 (0.37) | HDAC8HDAC4PLA2G7CYP3A4SMN1; SMN2 | |
| SCHEMBL5775799 | 0.89 | HDAC8 (0.34) | HDAC8PLA2G7PPARA | |
| SCHEMBL5775533 | 0.88 | HDAC8 (0.33) | HDAC8HDAC4PLA2G7PPARAMCHR1 | |
| SCHEMBL5774897 | 0.88 | MPO (0.35) | HDAC8HDAC4PLA2G7CYP3A4 | |
| SCHEMBL5774087 | 0.87 | CNR1 (0.36) | HDAC8PPARAHCRTR1HCRTR2 | |
| SCHEMBL5777281 | 0.85 | HDAC8 (0.34) | HDAC8CYP3A4KDM4E | |
| SCHEMBL5773577 | 0.85 | NAMPT (0.35) | HDAC8HDAC4 | |
| SCHEMBL5773350 | 0.83 | TSHR (0.40) | PLA2G7CYP3A4 | |
| SCHEMBL5773778 | 0.83 | PLA2G7 (0.36) | HDAC8HDAC4PLA2G7CYP3A4KDM4E | |
| SCHEMBL5774849 | 0.83 | HDAC4 (0.33) | HDAC8HDAC4KDM4EHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | HDAC8 639/4885HDAC4 434/4885PLA2G7 2423/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | HDAC8 569/4885HDAC4 497/4885PLA2G7 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.